CARLO®, which stands for ‘Cold Ablation Robot-guided Laser Osteotome’, is a high-tech robot system with which human bones can be cut with extreme precision but without contact, by means of nothing but lasers. CARLO® was developed by AOT AG (Advanced Osteotomy Tools) of Switzerland. Offering maximum patient safety, this system for laser-assisted, touchless surgery offers […]

Since November 2020, Dr. André Zimmermann has written a regular column on the topic of medtech for the magazine medtech zwo. As a business development expert in the healthcare sector, Dr. Zimmermann is well-connected worldwide. With a Ph.D. in the natural sciences, he aids SHS portfolio companies in the growth and SME sector with direct, […]

In December 2020, healthcare investor SHS sold its 100% stake in the Rosenheim, Germany-based medtech specialist puracon GmbH to Klingel medical metal group. With packaging and validation solutions by full-service provider puracon, the Klingel medical metal group can offer its medtech customers a complete package of services from a single source. You can learn more […]

For years, SHS has offered students an opportunity to complete an internship during the course of their studies. We offer young, motivated people a real-world insight into the fields of venture capital and private equity. This is how we contribute towards the professional development of future achievers. Vera Schlenker has been with SHS since November […]

We welcome our new colleague, Katharina Kolenda, who since 1 September 2020 has been completing her apprenticeship with us as an office management clerk. Ms Kolenda will work in all of the stations in the SHS back office and will be supervised by our experienced trainer, Regine Hujer, for whom the training of young people […]

Impact investing and ESG are growing increasingly important. By all appearances, the trend towards impact-oriented and sustainable investment is unstoppable. Reason enough to talk to a company that since its inception has been pursuing an investment approach focused on financial returns, on the one hand, but is also concerned about the social impact of the […]

Editorial staff: The year 2020 was marked by the occasionally dramatic effects of the coronavirus pandemic. According to the German Federal Statistical Office, the economy has declined by around 5 percent, making this the second largest drop after the 2008/2009 financial crisis. How would you describe your experience this year at SHS? Uwe Steinbacher: We […]

SHS Gesellschaft für Beteiligungsmanagement mbH (SHS) has sold its shares in the Austrian life science supplier Single Use Support GmbH (SUS) to Pall Corporation. SUS sets new standards for the transport of liquid substances in the medtech industry with its products, a success story Life science, biotech, pharmaceutical and medical device companies worldwide now use […]

The Tübingen-based medtech investor SHS is investing in Blue Ocean Spine GmbH, a developer for 3D-printed spinal implants Blue Ocean Spine is developing a portfolio of new spinal implants that can be precisely adapted to patient needs in situ or administered without additional means of fixation such as screws For Guntmar Eisen, a serial entrepreneur […]

With a population of around 1.4 billion, the People’s Republic of China is an enormously attractive market for medtech and life-science products. For foreign firms, this presents not only great opportunities but risks as well. By: Dr André Zimmermann, partner at Tübingen-based industry investor SHS. He has developed global connections in the medical technology sector […]

ZDF TV reports in its heute Sendung (from min. 07:32) at prime time about our portfolio company GNA Biosolutions GmbH. The company has received emergency approval for its point-of-care test, which enables detection for COVID19 within 40 minutes.

German molecular diagnostics startup GNA Biosolutions has received Emergency Use Authorization (Sonderzulassung) from the German Federal Institute for Drugs and Medical Devices (BfArM) for the GNA Octea SARS-CoV-2 Test System. The new technology developed by GNA Biosolutions enables decentralized COVID-19 rapid tests in approximately 40 minutes without sacrificing sensitivity.